Dr. Bram D. Wieskopf, MD

Dr. Wieskopf practices at North Georgia Osteoporosis Center in Woodstock, Georgia.

Dr. Wieskopf's NPI, 1164472577, was assigned on May 10, 2006. Dr. Wieskopf holds Georgia license 045136.

Dr. Wieskopf's primary practice is North Georgia Osteoporosis Center, at 1192 Buckhead Xing, Woodstock, GA 30189. The practice phone is (678) 494-4450.

Dr. Wieskopf's primary practice is North Georgia Osteoporosis Center in Woodstock, Georgia. Dr. Wieskopf is also affiliated with Wellstar Kennestone Regional Medical Center. The medical group on file is North Georgia Internal Medicine. Dmand AI also links Dr. Wieskopf to 3 more hospitals and 2 home health agencies, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wieskopf practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Wieskopf's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Wieskopf is licensed in Georgia.

CMS data shows 3,881 Medicare services from Dr. Wieskopf across 20 procedure codes in 2024, for 591 Medicare patients. Medicare paid $259,375 for them. Every service was in an office.

CMS counts 591 Medicare patients who saw Dr. Wieskopf in 2024. The largest group is 65 to 74, with 325 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 0.90, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wieskopf's median patient age at 68, with 56% women.

In 2024, Dr. Wieskopf wrote 3,474 Medicare Part D claims for 491 patients. 86% of them were for generic drugs. CMS names the drug for 2,849 of them, across 80 drugs with 11 or more claims each, at $262,644 in total drug cost. In 2023, CMS named 4,325 claims across 107 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Wieskopf for performance year 2024, reported through an alternative payment model (APM). Dr. Wieskopf accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wieskopf as offering telehealth.

Dmand AI links Dr. Wieskopf to 7 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Alzheimer Disease, Diabetes Mellitus, Type 2 and Osteoarthritis. Eli Lilly and Company sponsors the most, 4. Open Payments lists research payments to Dr. Wieskopf that name 10 trials.

CMS Open Payments shows 294 general payments to Dr. Wieskopf from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. Amgen Inc. paid the most, $5,418. It also lists 14 research payments totaling $381,990 from 2021 to 2024, naming 10 clinical trials.